Trial Profile

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (P05670).

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ficlatuzumab (Primary)
Indications Liver metastases; Solid tumours
Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic

Most Recent Events

01 Oct 2012 Results have been presented at ESMO-2012 according to an AVEO Oncology media release.
14 Apr 2012 Additional lead trial investigator (Shefali Agarwal) identified as reported by ClinicalTrials.gov.
14 Apr 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com